NU 172

Drug Profile

NU 172

Alternative Names: NU172

Latest Information Update: 05 Oct 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Archemix Corporation
  • Developer ARCA biopharma Inc
  • Class Anticoagulants; Antithrombotics; Nucleotide aptamers
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 04 Oct 2012 Discontinued - Phase-I for Thrombosis in USA (IV)
  • 28 Jan 2009 Nuvelo has merged with ARCA biopharma to form ARCA biopharma Inc
  • 04 Jun 2008 Nuvelo initiates enrolment in a phase Ib trial for Thrombosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top